https://www.selleckchem.com/pr....oducts/golvatinib-e7
2) and EudraCT (2018-001085-42). - ClinicalTrials.gov (NCT03797872) and EudraCT (2018-001085-42). Predictive markers for treatment response and survival outcome have not been identified in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemoimmunotherapy. We aimed to evaluate whether imaging biomarkers of F-fluorodeoxyglucose ( F-FDG) positron emission tomography/computed tomography (PET/CT) and routinely assessed clinico-laboratory values were associated with clinical outcomes in patients with advanced NSC
Like
Comment
Share
